
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis Inc has reported a significant 41% quarter-over-quarter increase in NeXT Personal Dx volumes in Q4'25, exceeding previous expectations, which reflects the potential for continued growth driven by its commercial partnership with Tempus. The recent announcement of Medicare coverage and pricing for the NeXT Personal MRD test marks a pivotal moment, likely enhancing adoption rates and revenue generation, particularly in breast cancer diagnostics. Additionally, the demonstrated ability of NeXT Personal to detect minimal residual disease (MRD) in the critical 1-100 ppm range further establishes the test's value, reinforcing the company's prospects in the personalized medicine landscape.
Bears say
Personalis Inc's outlook is adversely impacted by a combination of slowing demand within the biopharmaceutical sector and operational challenges, culminating in a lowered revenue guidance for Q4 2025. The company's year-over-year revenue decline in pharmaceutical services, attributed to the conclusion of Moderna's melanoma trial enrollment, raises concerns regarding its capacity to sustain and grow its revenue streams. Additionally, persistent financial losses and the existence of debt on the balance sheet signal potential difficulties in maintaining profitability going forward, which could further challenge investor confidence in the stock.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares